



## **Patent for Intercell's proprietary Antigen Identification Program granted**

**Vienna, Austria, November 10, 2005** – Intercell AG today announced that the European Patent Office has granted a European Patent 1355930 entitled “A method for identification, isolation and production of antigens to a specific pathogen”. The patent protects the company's proprietary Antigen Identification Program, which uses antibodies from humans previously exposed to the pathogen for selection of vaccine antigens and targets for antibody therapies from genomic expression libraries of bacterial, viral and fungal pathogens with high medical importance. The unique strategic strength of the program is to employ the human immune system as a comprehensive discovery machine to identify protective antigens.

The Antigen Identification Program has already been used very successfully to identify new vaccine candidates for own development or development through strategic partnerships with key vaccine players like Merck&Co., Inc., and sanofi pasteur.

“It is one of our strategic focuses to protect and strengthen our key products and technologies by means of aggressive patent filing and prosecution”, states Alexander von Gabain, Chief Scientific Officer of Intercell. “We are pleased about the issuance of this patent which protects our Antigen Identification Technology AIP®. This enables a successful further discovery of both further important vaccine candidates and antibody therapies in the field of infectious diseases.”

### **About Intercell**

Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol “ICLL”.

For more information please visit: [www.intercell.com](http://www.intercell.com)

### **Contact Intercell AG:**

#### **Intercell AG**

Katharina Wieser

Head of Corporate Communication

Campus Vienna Biocenter 2 – A-1030 Vienna

P: +43-1-20620-303 – [kwieser@intercell.com](mailto:kwieser@intercell.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

